Edwards Lifescience Corp. (EW) is featured in
Kevin Downing’s piece in Value Line of
Aug. 28. The company provides
procedures and products for the treatment of critically ill heart
patients—worldwide. It is profiled at:
My 5-year Yahoo chart for EW shows an
impressive recovery from the market lows of 2008-2009 until a sideways trend
took over in mid-2011. See:
My 3-month chart (including MACD and RSI) suggests
a buying opportunity in a new upward trend may now forming for EW, so now is a
good time to watch the stock’s progress daily.
If you wish, visit Amazon for the review of my
14th book:
No comments:
Post a Comment